CLINICAL STUDIES WITH RECOMBINANT-DNA-DERIVED METHIONYL HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT CHILDREN

S. L. Kaplan; G. P. August; S. L. Blethen; D. R. Brown; R. L. Hintz; A. Johansen; L. P. Plotnick; L. E. Underwood; J. J. Bell; R. M. Blizzard; T. P. Foley; N. J. Hopwood; R. T. Kirkland; R. G. Rosenfeld; J. J. Van Wyk

doi:10.1016/S0140-6736(86)91098-6

CLINICAL STUDIES WITH RECOMBINANT-DNA-DERIVED METHIONYL HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT CHILDREN

S. L. Kaplan, G. P. August, S. L. Blethen, D. R. Brown, R. L. Hintz, A. Johansen, L. P. Plotnick, L. E. Underwood, J. J. Bell, R. M. Blizzard, T. P. Foley, N. J. Hopwood, R. T. Kirkland, R. G. Rosenfeld, J. J. Van Wyk

Research output: Contribution to journal › Article › peer-review

122 Scopus citations

Abstract

Thirty-six children with growth hormone deficiency were treated for up to 48 months with methionyl human growth hormone (hGH) synthesised by DNA recombinant methods. The growth rate for these children increased from 3·2±1·1 cm/yr to 10 · 5±2·2 cm/yr (mean±SD). This was similar to the effect of pituitary hGH in ten GH deficient children, 3·8±1·0 to 10·1±1·1 cm/yr. Serum somatomedin C rose from 0·26±0·23 U/ml to 0·79±0·53 U/ml after 6 months of methionyl-hGH therapy, similar to the effect of pituitary hGH. The incidence of antibody formation to methionyl-hGH was higher than that observed with pituitary hGH (Kabi) but poor growth was observed only in the one patient on methionyl-hGH who acquired high-titre high-binding-capacity antibodies to hGH. No consistent changes in levels of antibodies to Escherichia coli proteins were detected. No other allergic manifestations or systemic side-effects were demonstrable.

Original language	English (US)
Pages (from-to)	697-700
Number of pages	4
Journal	The Lancet
Volume	327
Issue number	8483
DOIs	https://doi.org/10.1016/S0140-6736(86)91098-6
State	Published - Mar 29 1986
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(86)91098-6

Cite this

Kaplan, S. L., August, G. P., Blethen, S. L., Brown, D. R., Hintz, R. L., Johansen, A., Plotnick, L. P., Underwood, L. E., Bell, J. J., Blizzard, R. M., Foley, T. P., Hopwood, N. J., Kirkland, R. T., Rosenfeld, R. G., & Van Wyk, J. J. (1986). CLINICAL STUDIES WITH RECOMBINANT-DNA-DERIVED METHIONYL HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT CHILDREN. The Lancet, 327(8483), 697-700. https://doi.org/10.1016/S0140-6736(86)91098-6

Kaplan, SL, August, GP, Blethen, SL, Brown, DR, Hintz, RL, Johansen, A, Plotnick, LP, Underwood, LE, Bell, JJ, Blizzard, RM, Foley, TP, Hopwood, NJ, Kirkland, RT, Rosenfeld, RG & Van Wyk, JJ 1986, 'CLINICAL STUDIES WITH RECOMBINANT-DNA-DERIVED METHIONYL HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT CHILDREN', The Lancet, vol. 327, no. 8483, pp. 697-700. https://doi.org/10.1016/S0140-6736(86)91098-6

@article{9705d0e4e0724385a373d9e8deb7cfd6,

title = "CLINICAL STUDIES WITH RECOMBINANT-DNA-DERIVED METHIONYL HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT CHILDREN",

abstract = "Thirty-six children with growth hormone deficiency were treated for up to 48 months with methionyl human growth hormone (hGH) synthesised by DNA recombinant methods. The growth rate for these children increased from 3·2±1·1 cm/yr to 10 · 5±2·2 cm/yr (mean±SD). This was similar to the effect of pituitary hGH in ten GH deficient children, 3·8±1·0 to 10·1±1·1 cm/yr. Serum somatomedin C rose from 0·26±0·23 U/ml to 0·79±0·53 U/ml after 6 months of methionyl-hGH therapy, similar to the effect of pituitary hGH. The incidence of antibody formation to methionyl-hGH was higher than that observed with pituitary hGH (Kabi) but poor growth was observed only in the one patient on methionyl-hGH who acquired high-titre high-binding-capacity antibodies to hGH. No consistent changes in levels of antibodies to Escherichia coli proteins were detected. No other allergic manifestations or systemic side-effects were demonstrable.",

author = "Kaplan, {S. L.} and August, {G. P.} and Blethen, {S. L.} and Brown, {D. R.} and Hintz, {R. L.} and A. Johansen and Plotnick, {L. P.} and Underwood, {L. E.} and Bell, {J. J.} and Blizzard, {R. M.} and Foley, {T. P.} and Hopwood, {N. J.} and Kirkland, {R. T.} and Rosenfeld, {R. G.} and {Van Wyk}, {J. J.}",

year = "1986",

month = mar,

day = "29",

doi = "10.1016/S0140-6736(86)91098-6",

language = "English (US)",

volume = "327",

pages = "697--700",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8483",

}

TY - JOUR

T1 - CLINICAL STUDIES WITH RECOMBINANT-DNA-DERIVED METHIONYL HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT CHILDREN

AU - Kaplan, S. L.

AU - August, G. P.

AU - Blethen, S. L.

AU - Brown, D. R.

AU - Hintz, R. L.

AU - Johansen, A.

AU - Plotnick, L. P.

AU - Underwood, L. E.

AU - Bell, J. J.

AU - Blizzard, R. M.

AU - Foley, T. P.

AU - Hopwood, N. J.

AU - Kirkland, R. T.

AU - Rosenfeld, R. G.

AU - Van Wyk, J. J.

PY - 1986/3/29

Y1 - 1986/3/29

N2 - Thirty-six children with growth hormone deficiency were treated for up to 48 months with methionyl human growth hormone (hGH) synthesised by DNA recombinant methods. The growth rate for these children increased from 3·2±1·1 cm/yr to 10 · 5±2·2 cm/yr (mean±SD). This was similar to the effect of pituitary hGH in ten GH deficient children, 3·8±1·0 to 10·1±1·1 cm/yr. Serum somatomedin C rose from 0·26±0·23 U/ml to 0·79±0·53 U/ml after 6 months of methionyl-hGH therapy, similar to the effect of pituitary hGH. The incidence of antibody formation to methionyl-hGH was higher than that observed with pituitary hGH (Kabi) but poor growth was observed only in the one patient on methionyl-hGH who acquired high-titre high-binding-capacity antibodies to hGH. No consistent changes in levels of antibodies to Escherichia coli proteins were detected. No other allergic manifestations or systemic side-effects were demonstrable.

AB - Thirty-six children with growth hormone deficiency were treated for up to 48 months with methionyl human growth hormone (hGH) synthesised by DNA recombinant methods. The growth rate for these children increased from 3·2±1·1 cm/yr to 10 · 5±2·2 cm/yr (mean±SD). This was similar to the effect of pituitary hGH in ten GH deficient children, 3·8±1·0 to 10·1±1·1 cm/yr. Serum somatomedin C rose from 0·26±0·23 U/ml to 0·79±0·53 U/ml after 6 months of methionyl-hGH therapy, similar to the effect of pituitary hGH. The incidence of antibody formation to methionyl-hGH was higher than that observed with pituitary hGH (Kabi) but poor growth was observed only in the one patient on methionyl-hGH who acquired high-titre high-binding-capacity antibodies to hGH. No consistent changes in levels of antibodies to Escherichia coli proteins were detected. No other allergic manifestations or systemic side-effects were demonstrable.

UR - http://www.scopus.com/inward/record.url?scp=0022590488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022590488&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(86)91098-6

DO - 10.1016/S0140-6736(86)91098-6

M3 - Article

C2 - 2870221

AN - SCOPUS:0022590488

SN - 0140-6736

VL - 327

SP - 697

EP - 700

JO - The Lancet

JF - The Lancet

IS - 8483

ER -

CLINICAL STUDIES WITH RECOMBINANT-DNA-DERIVED METHIONYL HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT CHILDREN

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this